Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference |
| [13-January-2026] |
BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT (1:30 p.m. ET).
Further details, including slides, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events. About Ginkgo Bioworks Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Ginkgo Bioworks Contacts: INVESTOR CONTACT: MEDIA CONTACT:
SOURCE Ginkgo Bioworks | ||
Company Codes: NYSE:DNA |
View original content to download multimedia:
